These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28862642)

  • 1. Isolated polycystic liver disease genes define effectors of polycystin-1 function.
    Besse W; Dong K; Choi J; Punia S; Fedeles SV; Choi M; Gallagher AR; Huang EB; Gulati A; Knight J; Mane S; Tahvanainen E; Tahvanainen P; Sanna-Cherchi S; Lifton RP; Watnick T; Pei YP; Torres VE; Somlo S
    J Clin Invest; 2017 Sep; 127(9):3558. PubMed ID: 28862642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated polycystic liver disease genes define effectors of polycystin-1 function.
    Besse W; Dong K; Choi J; Punia S; Fedeles SV; Choi M; Gallagher AR; Huang EB; Gulati A; Knight J; Mane S; Tahvanainen E; Tahvanainen P; Sanna-Cherchi S; Lifton RP; Watnick T; Pei YP; Torres VE; Somlo S
    J Clin Invest; 2017 May; 127(5):1772-1785. PubMed ID: 28375157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms of Isolated Polycystic Liver Diseases.
    Yu Z; Shen X; Hu C; Zeng J; Wang A; Chen J
    Front Genet; 2022; 13():846877. PubMed ID: 35571028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRKCSH/80K-H, the protein mutated in polycystic liver disease, protects polycystin-2/TRPP2 against HERP-mediated degradation.
    Gao H; Wang Y; Wegierski T; Skouloudaki K; Pütz M; Fu X; Engel C; Boehlke C; Peng H; Kuehn EW; Kim E; Kramer-Zucker A; Walz G
    Hum Mol Genet; 2010 Jan; 19(1):16-24. PubMed ID: 19801576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease.
    Janssen MJ; Waanders E; Te Morsche RH; Xing R; Dijkman HB; Woudenberg J; Drenth JP
    Gastroenterology; 2011 Dec; 141(6):2056-2063.e2. PubMed ID: 21856269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease.
    Waanders E; te Morsche RH; de Man RA; Jansen JB; Drenth JP
    Hum Mutat; 2006 Aug; 27(8):830. PubMed ID: 16835903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal hepatocystin caused by truncating PRKCSH mutations leads to autosomal dominant polycystic liver disease.
    Drenth JP; Tahvanainen E; te Morsche RH; Tahvanainen P; Kääriäinen H; Höckerstedt K; van de Kamp JM; Breuning MH; Jansen JB
    Hepatology; 2004 Apr; 39(4):924-31. PubMed ID: 15057895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation.
    Fedeles SV; Tian X; Gallagher AR; Mitobe M; Nishio S; Lee SH; Cai Y; Geng L; Crews CM; Somlo S
    Nat Genet; 2011 Jun; 43(7):639-47. PubMed ID: 21685914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics of polycystic liver diseases.
    Lee-Law PY; van de Laarschot LFM; Banales JM; Drenth JPH
    Curr Opin Gastroenterol; 2019 Mar; 35(2):65-72. PubMed ID: 30652979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. It's not all in the cilium, but on the road to it: genetic interaction network in polycystic kidney and liver diseases and how trafficking and quality control matter.
    Bergmann C; Weiskirchen R
    J Hepatol; 2012 May; 56(5):1201-1203. PubMed ID: 22133568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of heterozygosity is present in SEC63 germline carriers with polycystic liver disease.
    Janssen MJ; Salomon J; Te Morsche RH; Drenth JP
    PLoS One; 2012; 7(11):e50324. PubMed ID: 23209713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-exome sequencing reveals LRP5 mutations and canonical Wnt signaling associated with hepatic cystogenesis.
    Cnossen WR; te Morsche RH; Hoischen A; Gilissen C; Chrispijn M; Venselaar H; Mehdi S; Bergmann C; Veltman JA; Drenth JP
    Proc Natl Acad Sci U S A; 2014 Apr; 111(14):5343-8. PubMed ID: 24706814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis.
    Sierks D; Schönauer R; Friedrich A; Hantmann E; de Fallois J; Linder N; Fischer J; Herber A; Bergmann C; Berg T; Halbritter J
    JHEP Rep; 2022 Nov; 4(11):100579. PubMed ID: 36246085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Congenital disorders of glycosylation in hepatology: the example of polycystic liver disease.
    Janssen MJ; Waanders E; Woudenberg J; Lefeber DJ; Drenth JP
    J Hepatol; 2010 Mar; 52(3):432-40. PubMed ID: 20138683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [From gene to disease; hepatocystin and autosomal dominant polycystic liver disease].
    Jansen JB; Morsche RH; Drenth JP
    Ned Tijdschr Geneeskd; 2003 Jul; 147(29):1408-12. PubMed ID: 12894465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic second-hit mutations leads to polycystic liver diseases.
    Banales JM; Munoz-Garrido P; Bujanda L
    World J Gastroenterol; 2013 Jan; 19(1):141-3. PubMed ID: 23326178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into Autosomal Dominant Polycystic Kidney Disease from Genetic Studies.
    Lanktree MB; Haghighi A; di Bari I; Song X; Pei Y
    Clin J Am Soc Nephrol; 2021 May; 16(5):790-799. PubMed ID: 32690722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver cyst gene knockout in cholangiocytes inhibits cilium formation and Wnt signaling.
    Wills ES; Te Morsche RHM; van Reeuwijk J; Horn N; Geomini I; van de Laarschot LFM; Mans DA; Ueffing M; Boldt K; Drenth JPH; Roepman R
    Hum Mol Genet; 2017 Nov; 26(21):4190-4202. PubMed ID: 28973524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management.
    Cnossen WR; Drenth JP
    Orphanet J Rare Dis; 2014 May; 9():69. PubMed ID: 24886261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
    Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
    JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.